ARKGvsXBIETF Comparison
VS
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. ARKG's top 1 sector exposures are Healthcare. In contrast, XBI's top sector exposures are Healthcare and Finance. ARKG is more expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.35% for XBI. ARKG is up 60.61% year-to-date (YTD) with +$136M in YTD flows. XBI performs worse with 32.87% YTD performance, and +$966M in YTD flows. Run a side-by-side ETF comparison of ARKG and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
ARKG vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/08/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG XBI | +5.74%+2.44% | +41.47%+26.14% | +60.61%+32.87% | +84.14%+72.26% | +50.72%+107.12% | -43.73%+23.20% |
| Flows | ARKG XBI | +$110M+$531M | +$210M+$1.35B | +$136M+$966M | +$151M+$1.73B | -$431M+$26M | -$2.19B+$1.69B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG XBI | +43.03%+29.80% | +44.26%+27.90% | +43.95%+28.27% | +46.35%+32.90% |
| Max drawdown | ARKG XBI | -13.89%-10.46% | -27.52%-10.46% | -46.41%-32.94% | -78.11%-53.28% |
| Max drawdown duration | ARKG XBI | 32d40d | 126d40d | 882d331d | 1825d1622d |
Trading data
ARKG | XBI | |
Last sale 9/9/2026 at 1:30 PM | $46.31 | $159.38 |
| Previous close 09/08/2026 | $46.85 | $161.93 |
| Consolidated volume 09/08/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
ARKG
is actively managed and doesn’t replicate an indexARKG | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/9/2026 at 1:30 PM
Live
Closed
ARKG | XBI | |
|---|---|---|
| Last price | $46.31 | $159.38 |
| 1D performance | -1.15% | -1.57% |
| AuM | $1.99 B | $11.33 B |
| E/R | 0.75% | 0.35% |
Characteristics
ARKG | XBI | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Ark Investment | State Street Investment Management |
| Benchmark | - | S&P Biotechnology Select Industry Index |
| N° of holdings | 31 | 149 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
ARKG
USA
88.43%
Other
11.57%
XBI
USA
95.3%
Other
4.7%
Sectors
ARKG
Healthcare
97.99%
Other
2.01%
XBI
Healthcare
99.41%
Other
0.59%
Advertisement
Diversification
ARKG
Total weight of top 15 holdings out of 15
75.55%
XBI
Total weight of top 15 holdings out of 15
20.29%
Top 15 holdings
Data as of July 31, 2026
ARKG
10X Genomics, Inc.
9.41%
Twist Bioscience Corp.
7.74%
Tempus AI, Inc.
6.57%
CRISPR Therapeutics AG
6.30%
Personalis, Inc.
5.48%
Absci Corp.
5.15%
Guardant Health, Inc.
4.75%
Illumina, Inc.
4.75%
Eli Lilly & Co.
4.69%
CareDx, Inc.
4.31%
Natera, Inc.
4.14%
Beam Therapeutics, Inc.
3.78%
Compass Pathways Plc
3.26%
Recursion Pharmaceuticals, Inc.
2.63%
Adaptive Biotechnologies Corp.
2.58%
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
Frequently asked questions about ARKG and XBI
How have the ARKG and XBI ETFs performed in 2026?
As of September 8, 2026, ARKG is up 60.61% year-to-date (YTD), while XBI has returned 32.87%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: ARKG or XBI?
Year-to-date, the ARKG ETF saw +$136M in flows, compared to +$966M for XBI.
Which ETF is more volatile: ARKG or XBI?
Over the past year, ARKG had a volatility of 44.26%, while XBI experienced 27.9%.
Which ETF is bigger: ARKG or XBI?
As of September 8, 2026, ARKG holds $1.99 B in assets under management (AUM), while XBI manages $11.33 B.
What sectors do the ARKG and XBI ETFs invest in?
ARKG leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the ARKG ETF and XBI ETF?
ARKG top holdings include 10X Genomics, Inc., Twist Bioscience Corp. and Tempus AI, Inc.. XBI holds in its top three: Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc..
Which ETF is more diversified: ARKG or XBI?
ARKG holds 31 securities with 75.55% of its assets in the top 15. XBI has 151 securities and a top 15 weight of 20.29%.
Advertisement
Latest news about ARKG & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
ARKG
XBI
Advertisement
Advertisement
